Jakob Bjorner, MD, PhD

Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit, Burden, and Satisfaction in Patients With Schizophrenia

Background: An open-label extension study (NCT02873208) evaluated the long-term tolerability, safety, and efficacy of combination olanzapine/samidorphan (OLZ/SAM) treatment in patients wi...

Leona Bessonova , PhD;

Amy O'Sullivan , PhD;

David McDonnell , MD;

Cory Saucier , MPH;

Michelle White , PhD;

April Foster , BS;

Jakob Bjorner , MD, PhD;

Olga Lapeyra , MD, CCRP;

David Walling , PhD, CNS, MD;

Adam Simmons , MPH;

Julia Carpenter-Conlin , MSW;

10/08/2020

Treatment Experiences of Individuals With Schizophrenia: Findings From an Online Survey

Background: This study examined experiences of patients living with schizophrenia with a history of oral antipsychotic medication (OAM) use.

Julia Carpenter-Conlin , MSW;

Leona Bessonova , PhD;

Jakob Bjorner , MD, PhD;

Dawn Velligan , PhD;

Michael Doane , PhD;

Martha Sajatovic , MD;

Stephen Maher , PhD;

Asia Sikora Kessler , PhD;

11/22/2019

Effect of Tardive Dyskinesia on Quality of Life: Patient-Reported Symptom Severity Is Associated With Physical, Mental, and Social Functioning Deficits

Background: Tardive dyskinesia (TD), an often-irreversible movement disorder typically caused by exposure to antipsychotics, most commonly affects the face, mouth, and tongue, and may be ...

Avery Rizio , PhD;

Jakob Bjorner , MD, PhD;

Stephen Maher , PhD;

Mark Kosinski , DPM, FIDSA, MA;

Sanjay K. Gandhi , MD, PhD;

Joseph McEvoy , MD;

Benjamin Carroll , PharmD;

03/01/2019